Skip to main content Accessibility help
×
Home
  • Print publication year: 2013
  • Online publication date: June 2013

Chapter 3 - Medical management of movement disorders

from Section 2 - Intervention options

Related content

Powered by UNSILO

References

1. FoxSH, KatzenschlagerR, LimSY, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2011;26:S2–41.
2. FreedCR, GreenePE, BreezeRE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. New Engl J Med 2001;344:710–19.
3. OlanowCW, GoetzCG, KordowerJH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54:403–14.
4. OlanowCW, HauserRA, GaugerL, et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995;38:771–7.
5. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Ann Neurol 1996;39:29–36.
6. ShoulsonI, OakesD, FahnS, et al; Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson’s disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604–12.
7. PalhagenS, HeinonenE, HagglundJ, et al. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66:1200–6.
8. ZhaoYJ, WeeHL, AuWL, et al. Selegiline use is associated with a slower progression in early Parkinson’s disease as evaluated by Hoehn and Yahr Stage transition times. Parkinsonism Relat Disord 2011;17:194–7.
9. OlanowCW, RascolO, HauserR, et al. ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. New Engl J Med 2009;361:1268–78.
10. Movement Disorder Society. Anticholinergic therapies in the treatment of Parkinson’s disease. Management of Parkinson’s disease: an evidence-based review. Mov Disord 2002;17:S7–12.
11. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000;284:1931–8.
12. RascolO, BrooksDJ, KorczynAD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484–91.
13. AhlskogJE, MuenterMD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448–58.
14. JennerP. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62:S47–55.
15. OlanowCW, ObesoJA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson’s disease: implications for the early use of COMT inhibitors. Neurology 2000;55:S72–7; discussion S78–81.
16. StocchiF, RascolO, KieburtzK, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18–27.
17. Movement Disorder Society. Amantadine and other antiglutamate agents: management of Parkinson’s disease. Management of Parkinson’s disease: an evidence-based review. Mov Disord 2002;17:S13–22.
18. SchapiraAH, OlanowCW. Drug selection and timing of initiation of treatment in early Parkinson’s disease. Ann Neurol 2008;64:S47–55.
19. CrawfordP, ZimmermanEE. Differentiation and diagnosis of tremor. Am Fam Physician 2011;83:697–702.
20. ZesiewiczTA, ElbleRJ, LouisED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. Neurology 2011;77:1752–5.
21. FahnS, JankovicJ. Tremors: diagnosis and treatment. In FahnS, JankovicJ, eds. Principles and Practice of Movement Disorders. Philadelphia: Churchill Livingstone Elsevier, 2007;451–78.
22. FahnS, JankovicJ. Dystonia: phenomenology, classification, etiology, pathology, biochemistry and genetics. In: FahnS, JankovicJ, eds. Principles and Practice of Movement Disorders. Philadelphia: Churchill Livingstone Elsevier, 2007;307–44.
23. ManjiH, HowardRS, MillerDH, et al. Status dystonicus: the syndrome and its management. Brain 1998;121:243–52.
24. TarsyD, SimonDK. Dystonia. New Engl J Med 2006;355:818–29.
25. AlbaneseA, AsmusF, BhatiaKP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 2011;18:5–18.
26. BalashY, GiladiN. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 2004;11:361–70.
27. AlbaneseA, BarnesMP, BhatiaKP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006;13:433–44.
28. BraininM, BarnesM, BaronJC, et al; Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004. Eur J Neurol 2004;11:577–81.
29. WalkerFO. Huntington’s disease. Lancet 2007;369:218–28.
30. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.
31. MestreTA, FerreiraJJ. An evidence-based approach in the treatment of Huntington’s disease. Parkinsonism Relat Disord 2011 Dec 15.
32. RossCA, TabriziSJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10:83–98.
33. CuboE, ShannonKM, TracyD, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006;67:1268–71.